Stock CLXT CIBUS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Cibus, Inc. Nasdaq

Equities

CLXT

US17166A1016

Advanced Medical Equipment & Technology

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-24 EDT 		5-day change 1st Jan Change
9.56 USD -4.40% Intraday chart for Cibus, Inc. +1.81% -51.32%
05-30 Cibus? White Mold (Sclerotinia) Resistance Trait Program Confirms Important Milestone for Next Generation Gene Edits in Canola CI
05-09 Cibus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 231 156.4 82.02 7.204 372.1 219 - -
Enterprise Value (EV) 1 191 147.2 82.02 7.204 372.1 219 219 219
P/E ratio -5.79 x -3.2 x -2.73 x -0.4 x -0.76 x -3.13 x -4.07 x -6.27 x
Yield - - - - - - - -
Capitalization / Revenue 31.7 x 6.56 x 3.16 x 45.9 x 205 x 101 x 25.2 x 5.2 x
EV / Revenue 31.7 x 6.56 x 3.16 x 45.9 x 205 x 101 x 25.2 x 5.2 x
EV / EBITDA -6.07 x -4.94 x -3.3 x -0.43 x -7.64 x -4.45 x -4.38 x -
EV / FCF -6,614,793 x -3,440,853 x - - - - - -
FCF Yield -0% -0% - - - - - -
Price to Book 3.68 x 3.88 x - - - - - -
Nbr of stocks (in thousands) 659 741 770 977 18,946 22,913 - -
Reference price 2 350.5 211.0 106.5 7.375 19.64 9.560 9.560 9.560
Announcement Date 20-03-05 21-03-04 22-03-03 23-03-02 24-03-21 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 7.296 23.85 25.99 0.157 1.817 2.167 8.69 42.16
EBITDA 1 -38.07 -31.64 -24.86 -16.84 -48.68 -49.2 -50 -
EBIT 1 -39.67 -43.83 -29.33 -22.37 -69.46 -60.25 -51.2 -15
Operating Margin -543.76% -183.77% -112.87% -14,248.41% -3,823% -2,780.34% -589.18% -35.58%
Earnings before Tax (EBT) 1 -39.61 -44.84 -29.2 -16.89 -337.6 -88.98 -94.97 -67.08
Net income 1 -39.61 -44.84 -29.2 -16.89 -267.6 -82.37 -88.07 -63.73
Net margin -542.93% -187.98% -112.36% -10,758.6% -14,729.06% -3,800.98% -1,013.46% -151.18%
EPS 2 -60.50 -66.00 -39.00 -18.50 -25.95 -3.050 -2.350 -1.525
Free Cash Flow -34.92 -45.46 - - - - - -
FCF margin -478.62% -190.59% - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 20-03-05 21-03-04 22-03-03 23-03-02 24-03-21 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 1.943 0.032 0.041 0.042 0.042 - 0.475 1.103 0.545 0.44 0.484 0.532
EBITDA -5.273 -4.895 -4.932 -4.61 -1.829 - -18.28 -13.65 - - - -
EBIT -6.71 -6.089 -6.765 -6.203 -3.313 - -25.8 -19.89 -18.45 - - -
Operating Margin -345.34% -19,028.12% -16,500% -14,769.05% -7,888.1% - -5,430.95% -1,803.54% -3,385.87% - - -
Earnings before Tax (EBT) 1 -7.057 -5.619 -2.485 -5.95 -2.837 - -34.53 -277.2 -26.96 -27.42 -27.84 -28.12
Net income 1 -7.057 -5.619 -2.485 -5.95 -2.837 -18.69 -26.43 -217.1 -23.44 -27.42 -27.84 -28.12
Net margin -363.2% -17,559.38% -6,060.98% -14,166.67% -6,754.76% - -5,564% -19,683.95% -4,300% -6,230.68% -5,751.65% -5,284.77%
EPS 2 -9.000 -6.500 -2.500 -6.500 -3.000 -3.050 -1.590 -19.62 -1.120 -0.8100 -0.7600 -0.5250
Dividend per Share - - - - - - - - - - - -
Announcement Date 22-03-03 22-05-05 22-08-04 22-11-03 23-03-02 23-08-10 23-11-09 24-03-21 24-05-09 - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position 40 9.24 - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow -34.9 -45.5 - - - - - -
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 95.30 54.40 - - - - - -
Cash Flow per Share -48.70 -64.40 - - - - - -
Capex 2.97 1.79 - - - - - -
Capex / Sales 40.69% 7.49% - - - - - -
Announcement Date 20-03-05 21-03-04 22-03-03 23-03-02 24-03-21 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Cibus, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
9.56 USD
Average target price
23 USD
Spread / Average Target
+140.59%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+6.62% 216B
DANAHER CORPORATION Stock Danaher Corporation
+10.99% 190B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+27.18% 152B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+32.69% 113B
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
+1.71% 64.04B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+18.26% 54.34B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
+1.63% 49.21B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-2.84% 39.41B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+1.98% 35.99B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. CLXT Stock
  4. CLXT Stock
  5. Financials Cibus, Inc.